Prostate Cancer Metastatic Clinical Trial
Official title:
REALITY Study: Analysis of a Prospective REgistry to Assess Outcome and Toxicity of Targeted RadionucLide TherapY in Patients With mCRPC in Clinical Routine.
This prospective registry aims to assess outcome and toxicity of targeted radionuclide therapies in patients with advanced prostate cancer in clinical routine. While the major investigated treatment modality is prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, also other radionuclide therapies such as Ra223 and liver-directed radioembolization are included. The investigators believe that prospectively assessed long-term outcome data on implementation of radionuclide therapy, especially in the palliative setting of advanced mCRPC, help to better define the real benefits and risks of the respective treatment modalities for patients regarding survival and quality-of-life.
Targeted radionuclide therapy is comprised of different modalities that may be applied in advanced prostate cancer, either targeting bone metastases (mainly using Radium-223), any site of metastases with PSMA-expression (ß- / alpha-emitter labelled radioligands) or loco-regionally applying internal radiation (Yttrium-90 microspheres) to metastatic liver disease. While in Germany, each form of treatment is used in clinical routine, data is sparse regarding the real benefits and risks of respective modalities, also when used in a sequential order. As an example, patients receiving Ra223 treatment may later undergo PSMA targeted radioligand therapy, with little data available on dependent response relationships or cumulative risks. Prospective assessment of outcomes and toxicities in a radionuclide therapy registry is apparently superior over retrospective analyses of selected patient populations. The goal of the REALITY study is to gain a better understanding of the real-life clinical application of radionuclide therapies, with a focus on PSMA-targeted radioligand therapy in a high-volume treatment centre, and the impact of each treatment for patient outcome. Based on primary and secondary outcome measures the potential prediction of treatment benefit by baseline patient and tumor characteristics, and early changes of biomarkers will be of interest. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
| Suspended |
NCT05361915 -
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05067140 -
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03646162 -
Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03413995 -
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
|
Phase 2 | |
| Not yet recruiting |
NCT06461689 -
Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer
|
||
| Recruiting |
NCT05078151 -
Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer
|
N/A | |
| Recruiting |
NCT03507595 -
Evaluation of the Metastasis and Recurrence of Prostate Cancer
|
||
| Completed |
NCT03362359 -
Ga-68-PSMA-11 in High-risk Prostate Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04116775 -
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
|
Phase 2 | |
| Completed |
NCT03223727 -
Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223
|
||
| Recruiting |
NCT04983095 -
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT04086290 -
National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03129139 -
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT04983628 -
Molecular Profiling in Prostate Cancer
|
||
| Active, not recruiting |
NCT03414437 -
Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)
|
||
| Completed |
NCT02485691 -
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
|
Phase 4 | |
| Completed |
NCT03693742 -
MSG Use With 18F-DCFPyL PET/CT Imaging
|
N/A | |
| Completed |
NCT01322490 -
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
|
Phase 3 | |
| Completed |
NCT03739684 -
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
|
Phase 3 |